BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...
Mozilla introduces an opt-in AI Window for Firefox, giving users full control over if and how they use AI, despite pushback ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback